Skip to content

Hydroxycarbamide

Droxia, Hydrea, Siklos (hydroxyurea) is a small molecule pharmaceutical. Hydroxyurea was first approved as Droxia on 1982-01-01. It is used to treat bcr-abl positive chronic myelogenous leukemia, brain neoplasms, essential thrombocythemia, head and neck neoplasms, and hypereosinophilic syndrome amongst others in the USA. The pharmaceutical is active against ribonucleoside-diphosphate reductase large subunit and ribonucleoside-diphosphate reductase subunit M2. In addition, it is known to target Methyl-accepting chemotaxis transmembrane sensory protein (MCP-like protein).
Trade Name Droxia, Hydrea, Siklos
Common Name Hydroxycarbamide
Indication bcr-abl positive chronic myelogenous leukemia, brain neoplasms, essential thrombocythemia, head and neck neoplasms, hypereosinophilic syndrome, leukocytosis, melanoma, non-small-cell lung carcinoma, ovarian neoplasms, polycythemia vera, prostatic neoplasms, psoriasis, renal cell carcinoma, squamous cell carcinoma, uterine neoplasms
Drug Class
Hydroxycarbamide
Get full access now